We included peer-reviewed randomized controlled trials, meta-analyses, and high-quality narrative or systematic reviews written in English that evaluated the effects of GLP-1 receptor agonists (liraglutide, semaglutide, or related analogues), as well as dual GIP/GLP-1 receptor agonists (such as tirzepatide), exercise training, or their combination on weight loss, body composition, metabolic, or cardiovascular outcomes in adults with obesity or type 2 diabetes
Users who expected the patch specifically to drive weight loss or mental clarity breakthroughs report disappointment
The Bottom Line The DiMarchi/Tschp paper does not invalidate GLP-1 drugs
Don't panic
Step-down strategies, maintenance dosing, and regular check-ins to monitor your metabolism are all part of the process
Osteoarthritis treatment via the GLP-1mediated gut-joint axis targets intestinal FXR signaling